Bone marrow stromal cells attenuate LPS-induced mouse acute liver injury via the prostaglandin E 2-dependent repression of the NLRP3 inflammasome in Kupffer cells

Immunology Letters

Volumn 179, Issue , 2016, Pages 102-113

  Miao, Chun mu ^a   Jiang, Xiao wei ^a   He, Kun ^a   Li, Pei zhi ^a   Liu, Zuo jin ^a   Cao, Ding ^a   Ou, Zhi bing ^a   Gong, Jian ping ^a   Liu, Chang an ^a   Cheng, Yao ^a  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Acute liver injury; BMSCs; Kupffer cells; NLRP3; PGE2

Indexed keywords

CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 3; PROSTAGLANDIN E2; BIOLOGICAL MARKER; CYTOKINE; INTERLEUKIN 1BETA CONVERTING ENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW STROMA CELL; CELL ACTIVATION; CELL THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; INTERLEUKIN 10 BLOOD LEVEL; KUPFFER CELL; LIVER FUNCTION; LIVER INJURY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN BLOOD LEVEL; THERAPY EFFECT; ACUTE DISEASE; ANIMAL; APOPTOSIS; BIOPSY; COCULTURE; DISEASE MODEL; IMMUNOLOGY; LIVER DISEASE; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY;

ACUTE DISEASE; ANIMALS; APOPTOSIS; BIOMARKERS; BIOPSY; CASPASE 1; COCULTURE TECHNIQUES; CYTOKINES; DINOPROSTONE; DISEASE MODELS, ANIMAL; INFLAMMASOMES; KUPFFER CELLS; LIPOPOLYSACCHARIDES; LIVER DISEASES; MALE; MESENCHYMAL STROMAL CELLS; MICE; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN;

EID: 84994309644     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2016.09.009     Document Type: Article

References (37)

1. [1] Nguyen, H.B., Smith, D., Sepsis in the 21st century: recent definitions and therapeutic advances. Am. J. Emerg. Med. 25:5 (2007), 564–571.
2. [2] Li, P., Zhang, Z., Gong, J., Zhang, Y., Zhu, X., S-Adenosylmethionine attenuates lipopolysaccharide-induced liver injury by downregulating the Toll-like receptor 4 signal in Kupffer cells. Hepatol. Int. 8:2 (2014), 275–284.
3. [3] Annane, D., Adjunctive treatment in septic shock: what's next. Presse Med. 45:4) Pt (2 (2016), e105–9.
4. [4] Schroder, K., Tschopp, J., The inflammasomes. Cell 140:6 (2010), 821–832.
5. [5] Shao, B.Z., Xu, Z.Q., Han, B.Z., Su, D.F., Liu, C., NLRP3 inflammasome and its inhibitors: a review. Front. Pharmacol., 6, 2015, 262.
6. [6] Luo, Y.P., Jiang, L., Kang, K., et al. Hemin inhibits NLRP3 inflammasome activation in sepsis-induced acute lung injury: involving heme oxygenase-1. Int. Immunopharmacol. 20:1 (2014), 24–32.
7. [7] Bauernfeind, F.G., Horvath, G., Stutz, A., et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183:2 (2009), 787–791.
8. [8] Haneklaus, M., O'Neill, L.A., Coll, R.C., Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Curr. Opin. Immunol. 25:1 (2013), 40–45.
9. [9] Sokolowska, M., Chen, L.Y., Liu, Y., et al. Prostaglandin E2 inhibits NLRP3 inflammasome activation through EP4 receptor and intracellular cyclic AMP in human macrophages. J. Immunol. 194:11 (2015), 5472–5487.
10. [10] Ivanov, A.I., Romanovsky, A.A., Prostaglandin E2 as a mediator of fever: synthesis and catabolism. Front. Biosci. 9 (2004), 1977–1993.
11. [11] Pistoia, V., Raffaghello, L., Unveiling the role of TNF-alpha in mesenchymal stromal cell-mediated immunosuppression. Eur. J. Immunol. 44:2 (2014), 352–356.
12. [12] Tyndall, A., Pistoia, V., Mesenchymal stem cells combat sepsis. Nat. Med. 15:1 (2009), 18–20.
13. [13] Nagaishi, K., Ataka, K., Echizen, E., Arimura, Y., Fujimiya, M., Mesenchymal stem cell therapy ameliorates diabetic hepatocyte damage in mice by inhibiting infiltration of bone marrow-derived cells. Hepatology 59:5 (2014), 1816–1829.
14. [14] Nemeth, K., Leelahavanichkul, A., Yuen, P.S., et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 15:1 (2009), 42–49.
15. [15] Edwards, J.P., Emens, L.A., The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE(2) in murine macrophages. Int. Immunopharmacol. 10:10 (2010), 1220–1228.
16. [16] Patel, S., Vetale, S., Teli, P., Mistry, R., Chiplunkar, S., IL-10 production in non-small cell lung carcinoma patients is regulated by ERK: P38 and COX-2. J. Cell. Mol. Med. 16:3 (2012), 531–544.
17. [17] Shindo, Y., Iwamoto, K., Mouri, K., et al. Conversion of graded phosphorylation into switch-like nuclear translocation via autoregulatory mechanisms in ERK signalling. Nat. Commun., 7, 2016, 10485.
18. [18] You, Y., Zhang, J., Gong, J., et al. Mesenchymal stromal cell-dependent reprogramming of Kupffer cells is mediated by TNF-alpha and PGE2 and is crucial for liver transplant tolerance. Immunol. Res. 62:3 (2015), 292–305.
19. [19] Li, P.Z., Li, J.Z., Li, M., Gong, J.P., He, K., An efficient method to isolate and culture mouse Kupffer cells. Immunol. Lett. 158:1-2 (2014), 52–56.
20. [20] Yao, Y., Vent-Schmidt, J., McGeough, M.D., et al. Tr1Cells: but not Foxp3+ regulatory T cells, suppress NLRP3 inflammasome activation via an IL-10-Dependent mechanism. J. Immunol. 195:2 (2015), 488–497.
21. [21] Mao, K., Chen, S., Chen, M., et al. Nitric oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock. Cell Res. 23:2 (2013), 201–212.
22. [22] Ahn, H., Kim, J., Jeung, E.B., Lee, G.S., Dimethyl sulfoxide inhibits NLRP3 inflammasome activation. Immunobiology 219:4 (2014), 315–322.
23. [23] Zhang, B., Liu, Y., Sui, Y.B., et al. Cortistatin inhibits NLRP3 inflammasome activation of cardiac fibroblasts during sepsis. J. Card. Fail. 21:5 (2015), 426–433.
24. [24] Wang, P., Huang, J., Li, Y., et al. Exogenous carbon monoxide decreases sepsis-induced acute kidney injury and inhibits NLRP3 inflammasome activation in rats. Int. J. Mol. Sci. 16:9 (2015), 20595–20608.
25. [25] Zagoura, D.S., Roubelakis, M.G., Bitsika, V., et al. Therapeutic potential of a distinct population of human amniotic fluid mesenchymal stem cells and their secreted molecules in mice with acute hepatic failure. Gut 61:6 (2012), 894–906.
26. [26] Meier, R.P., Mahou, R., Morel, P., et al. Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice. J. Hepatol. 62:3 (2015), 634–641.
27. [27] Bauernfeind, F., Ablasser, A., Bartok, E., et al. Inflammasomes: current understanding and open questions. Cell. Mol. Life Sci. 68:5 (2011), 765–783.
28. [28] Akiyama, K., Chen, C., Wang, D., et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 10:5 (2012), 544–555.
29. [29] Zhang, Y., Cai, W., Huang, Q., et al. Mesenchymal stem cells alleviate bacteria-induced liver injury in mice by inducing regulatory dendritic cells. Hepatology 59:2 (2014), 671–682.
30. [30] Omosun, Y., McKeithen, D., Ryans, K., et al. Interleukin-10 modulates antigen presentation by dendritic cells through regulation of NLRP3 inflammasome assembly during chlamydia infection. Infect. Immun. 83:12 (2015), 4662–4672.
31. [31] Gurung, P., Li, B., Subbarao, M.R.K., Lamkanfi, M., Geiger, T.L., Kanneganti, T.D., Chronic TLR stimulation controls NLRP3 inflammasome activation through IL-10 mediated regulation of NLRP3 expression and caspase-8 activation. Sci. Rep., 5, 2015, 14488.
32. [32] Filardy, A.A., He, J., Bennink, J., Yewdell, J., Kelsall, B.L., Posttranscriptional control of NLRP3 inflammasome activation in colonic macrophages. Mucosal. Immunol. 9:July (4) (2016), 850–858.
33. [33] Hsu, W.T., Lin, C.H., Chiang, B.L., Jui, H.Y., Wu, K.K., Lee, C.M., Prostaglandin E2 potentiates mesenchymal stem cell-induced IL-10 + IFN-gamma + CD4+ regulatory T cells to control transplant arteriosclerosis. J. Immunol. 190:5 (2013), 2372–2380.
34. [34] Zhang, S., Danchuk, S.D., Bonvillain, R.W., et al. Interleukin 6 mediates the therapeutic effects of adipose-derived stromal/stem cells in lipopolysaccharide-induced acute lung injury. Stem Cells 32:6 (2014), 1616–1628.
35. [35] Duijvestein, M., Wildenberg, M.E., Welling, M.M., et al. Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells 29:10 (2011), 1549–1558.
36. [36] Niu, J., Yue, W., Song, Y., et al. Prevention of acute liver allograft rejection by IL-10-engineered mesenchymal stem cells. Clin. Exp. Immunol. 176:3 (2014), 473–484.
37. [37] Keung, E.Z., Nelson, P.J., Conrad, C., Concise review: genetically engineered stem cell therapy targeting angiogenesis and tumor stroma in gastrointestinal malignancy. Stem Cells 31:2 (2013), 227–235.